Summary

Overview
Global Fatty Acid Oxidation Disorder Drugs Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Fatty Acid Oxidation Disorders (FAOD), also known as fatty acid oxidation deficits or fatty acid metabolism disorders, are a category of rare hereditary metabolic diseases that halt the body's ability to break down and turn fats into energy. Normally, the body uses fatty acids as its primary source of energy, especially when fasting or engaging in intense physical exercise. Individuals with FAODs, on the other hand, are deficient in one or more of the enzymes or transport proteins involved in the fatty acid oxidation pathway.
Fatty Acid Oxidation Disorders (FAOD) drugs are pharmaceutical treatments and therapies that are used to manage and mitigate the symptoms and consequences associated with FAOD. These medications are intended to enhance energy production, prevent toxic metabolite buildup, and treat symptoms such as muscle weakness, hypoglycemia, and metabolic crises.
Market Dynamics: Drivers and Restraints
The increasing number of product approvals
The increasing number of product approvals is expected to drive the fatty acid oxidation disorder (FAOD) drug market, as each approval extends treatment options, improves patient access, encourages competition, and boosts investor confidence. These approvals are the outcome of rigorous clinical trials, which provide patients with cutting-edge medicines while also driving additional R&D investments.
For instance, in January 2023, Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, stated that the US Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD). Thus, owing to the above factors the market is expected to drive over the forecast period.
Market Dynamics: Restraint
The limited patient pool is a major restraint to the fatty acid oxidation disorders (FAOD) drugs market. In comparison to more prevalent diseases, these uncommon hereditary metabolic abnormalities affect a small percentage of people. As a result, pharmaceutical companies face difficulties in establishing economies of scale and profitability in the research, development, and production of FAOD-specific drugs and therapies. Due to restricted competition and economies of scale, the small market size reduces financial incentives for companies to invest significant resources in FAOD drug research, potentially resulting in fewer treatment options and higher costs for patients.
Segment Analysis
The global fatty acid oxidation disorder drugs market is segmented based on type, drug type, route of administration, distribution channel and region.
The triheptanoin segment accounted for approximately 31.2% of the fatty acid oxidation disorder drugs market share
Triheptanoin segment is expected to dominate the fatty acid oxidation disorder (FAOD) drug market with market share of 31.2%. Triheptanoin, a metabolic modulator, has received considerable interest as a potentially effective treatment for long-chain FAODs and other forms of FAODs. It serves as an alternative energy source and aids in avoiding the metabolic problems caused by FAODs.
Furthermore, the increasing number product approvals and collaboration between the companies for this drug is expected to fuel the segment growth. For instance, in July 2020, Ultragenyx Pharmaceutical Inc. partnered with Orsini Pharmaceutical Services, a prominent independent national specialty pharmacy specializing in patients with rare and difficult disorders, as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi is approved for the treatment of pediatric and adult patients with molecularly proven long-chain fatty acid oxidation disorders (LC-FAOD) as a source of calories and fatty acids. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Penetration
North America accounted for approximately 37.4% of the market share in 2022
The North America region particulary the U.S. is expected to dominate the market owing to the factors such as, rise in product approvals, increasing number of clinical trial, and presence of key market players in this region
For instance, in June 2020, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, received FDA approval for Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD) as the first approved therapy.
Moreover, the increasing healthcare spending and growing population and awareness in Asia Pacific countries and government initiatives to promote awareness, and rise in the demand for the treatment are some of the other factors responsible for revenue growth of the market in the Asia Pacific region.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a major impact on the market for Fatty Acid Oxidation Disorder (FAOD) drugs. It caused delays in patient enrollment and data collecting in ongoing clinical trials. Manufacturing and distribution of FAOD medications were hampered by supply chain issues, potentially leading to shortages. Healthcare priorities have evolved, with resources allocated to COVID-19 management, affecting attention and funding for uncommon diseases such as FAODs. Due to lockdowns and limitations, diagnoses and treatments were delayed, creating hazards to FAOD patients.
FAOD patients, many of whom had underlying medical issues, faced additional risks and disturbances in their everyday lives. However, A study found that pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication, and identified fatty acid synthase inhibitors as drug candidates for the prevention and treatment of COVID-19.
Market Segmentation
By Type
• Short-Chain FAODs
• Medium-Chain FAODs
• Long-Chain FAODs
• Very Long-Chain FAODs
By Drug Type
• Levocarnitine
• Triheptanoin
• Dextrose
• Riboflavin
• Others
By Route of Administration
• Oral
• Intravenous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the fatty acid oxidation disorder drugs market include Pfizer Inc., Leadiant Biosciences, Inc., Ultragenyx Pharmaceutical Inc., Vitane Pharmaceuticals, Inc., Laboratorios Casasco, NEXTWELL PHARMACEUTICAL PRIVATE LIMITED, Action Labs, Inolex, Inc., Lonza Group Ltd, Northeast Pharmaceutical Group Co., Ltd., and among others.
Key Developments
• On January 31, 2023, Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, stated that the US Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain fatty acid oxidation disorder (LC-FAOD).
Why Purchase the Report?
• To visualize the global fatty acid oxidation disorder drugs market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of fatty acid oxidation disorder drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global fatty acid oxidation disorder drugs market report would provide approximately 69 tables, 69 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. he increasing number of product approvals
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. The availability of limited patient pool
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Epidemiology
5.2. Porter's Five Force Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Pipeline Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Short-Chain FAODs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Medium-Chain FAODs
7.4. Long-Chain FAODs
7.5. Very Long-Chain FAODs
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Levocarnitine*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Triheptanoin
8.4. Dextrose
8.5. Riboflavin
8.6. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intravenous
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Leadiant Biosciences, Inc.
13.3. Ultragenyx Pharmaceutical Inc.
13.4. Vitane Pharmaceuticals, Inc.
13.5. Laboratorios Casasco
13.6. NEXTWELL PHARMACEUTICAL PRIVATE LIMITED
13.7. Action Labs
13.8. Inolex, Inc.
13.9. Lonza Group Ltd
13.10. Northeast Pharmaceutical Group Co., Ltd.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us